AIMS: The aim of this study was to investigate the vascular effects of liraglutide in patients well controlled on metformin monotherapy. METHODS:Forty-four patients with Type 2 diabetes were included in the study. Main inclusion criteria were: pretreatment with metforminon a stable dosage, HbA(1c) < 53 mmol/mol (7.0%), age 30-65 years. Patients were randomized to receive additional liraglutide or to remain on metformin monotherapy. After 6 weeks (1.2 mg) and after 12 weeks (1.8 mg), venous blood was taken for the measurement of several laboratory markers characterizing vascular and endothelial function. In addition, retinal microvascular endothelial function and arterial stiffness were measured. RESULTS:HbA(1c) levels declined from 45 ± 4 mmol/mol (6.3 ± 0.4%; mean ± SD) to 40 ± 3 mmol/mol (5.8 ± 0.3%) during liraglutide treatment. Asymmetric dimethylarginin was reduced by liraglutide treatment from 0.39 ± 0.08 to 0.35 ± 0.06 μmol/l, E-selectin from 43.6 ± 15.4 to 40.8 ± 15.1 ng/ml, plasminogen activator inhibitor 1 from 861.6 ± 584.3 to 666.1 ± 499.4 ng/ml and intact proinsulin from 9.0 ± 7.2 to 7.0 ± 4.8 pmol/l at 12 weeks of treatment. The microvascular response to flicker light increased from 7.0 ± 15.1 to 15.4 ± 11.5% after 6 weeks and to 11.1 ± 9.9% after 12 weeks. No change could be observed for high-sensitivity C-reactive protein, monocyte chemotactic protein 1, vascular cell adhesion molecule or arterial stiffness parameters. CONCLUSIONS: In patients with Type 2 diabetes, well controlled with metformin monotherapy, addition of liraglutide improves several cardiovascular risk markers beyond glycaemic control.
RCT Entities:
AIMS: The aim of this study was to investigate the vascular effects of liraglutide in patients well controlled on metformin monotherapy. METHODS: Forty-four patients with Type 2 diabetes were included in the study. Main inclusion criteria were: pretreatment with metformin on a stable dosage, HbA(1c) < 53 mmol/mol (7.0%), age 30-65 years. Patients were randomized to receive additional liraglutide or to remain on metformin monotherapy. After 6 weeks (1.2 mg) and after 12 weeks (1.8 mg), venous blood was taken for the measurement of several laboratory markers characterizing vascular and endothelial function. In addition, retinal microvascular endothelial function and arterial stiffness were measured. RESULTS: HbA(1c) levels declined from 45 ± 4 mmol/mol (6.3 ± 0.4%; mean ± SD) to 40 ± 3 mmol/mol (5.8 ± 0.3%) during liraglutide treatment. Asymmetric dimethylarginin was reduced by liraglutide treatment from 0.39 ± 0.08 to 0.35 ± 0.06 μmol/l, E-selectin from 43.6 ± 15.4 to 40.8 ± 15.1 ng/ml, plasminogen activator inhibitor 1 from 861.6 ± 584.3 to 666.1 ± 499.4 ng/ml and intact proinsulin from 9.0 ± 7.2 to 7.0 ± 4.8 pmol/l at 12 weeks of treatment. The microvascular response to flicker light increased from 7.0 ± 15.1 to 15.4 ± 11.5% after 6 weeks and to 11.1 ± 9.9% after 12 weeks. No change could be observed for high-sensitivity C-reactive protein, monocyte chemotactic protein 1, vascular cell adhesion molecule or arterial stiffness parameters. CONCLUSIONS: In patients with Type 2 diabetes, well controlled with metformin monotherapy, addition of liraglutide improves several cardiovascular risk markers beyond glycaemic control.
Authors: Andreas Pfützner; Iris Hermanns; Sanja Ramljak; Filiz Demircik; Anke H Pfützner; Peter H Kann; Matthias M Weber Journal: J Diabetes Sci Technol Date: 2015-09-29
Authors: Robert A Scott; Daniel F Freitag; Li Li; Audrey Y Chu; Praveen Surendran; Robin Young; Niels Grarup; Alena Stancáková; Yuning Chen; Tibor V Varga; Hanieh Yaghootkar; Jian'an Luan; Jing Hua Zhao; Sara M Willems; Jennifer Wessel; Shuai Wang; Nisa Maruthur; Kyriaki Michailidou; Ailith Pirie; Sven J van der Lee; Christopher Gillson; Ali Amin Al Olama; Philippe Amouyel; Larraitz Arriola; Dominique Arveiler; Iciar Aviles-Olmos; Beverley Balkau; Aurelio Barricarte; Inês Barroso; Sara Benlloch Garcia; Joshua C Bis; Stefan Blankenberg; Michael Boehnke; Heiner Boeing; Eric Boerwinkle; Ingrid B Borecki; Jette Bork-Jensen; Sarah Bowden; Carlos Caldas; Muriel Caslake; L Adrienne Cupples; Carlos Cruchaga; Jacek Czajkowski; Marcel den Hoed; Janet A Dunn; Helena M Earl; Georg B Ehret; Ele Ferrannini; Jean Ferrieres; Thomas Foltynie; Ian Ford; Nita G Forouhi; Francesco Gianfagna; Carlos Gonzalez; Sara Grioni; Louise Hiller; Jan-Håkan Jansson; Marit E Jørgensen; J Wouter Jukema; Rudolf Kaaks; Frank Kee; Nicola D Kerrison; Timothy J Key; Jukka Kontto; Zsofia Kote-Jarai; Aldi T Kraja; Kari Kuulasmaa; Johanna Kuusisto; Allan Linneberg; Chunyu Liu; Gaëlle Marenne; Karen L Mohlke; Andrew P Morris; Kenneth Muir; Martina Müller-Nurasyid; Patricia B Munroe; Carmen Navarro; Sune F Nielsen; Peter M Nilsson; Børge G Nordestgaard; Chris J Packard; Domenico Palli; Salvatore Panico; Gina M Peloso; Markus Perola; Annette Peters; Christopher J Poole; J Ramón Quirós; Olov Rolandsson; Carlotta Sacerdote; Veikko Salomaa; María-José Sánchez; Naveed Sattar; Stephen J Sharp; Rebecca Sims; Nadia Slimani; Jennifer A Smith; Deborah J Thompson; Stella Trompet; Rosario Tumino; Daphne L van der A; Yvonne T van der Schouw; Jarmo Virtamo; Mark Walker; Klaudia Walter; Jean E Abraham; Laufey T Amundadottir; Jennifer L Aponte; Adam S Butterworth; Josée Dupuis; Douglas F Easton; Rosalind A Eeles; Jeanette Erdmann; Paul W Franks; Timothy M Frayling; Torben Hansen; Joanna M M Howson; Torben Jørgensen; Jaspal Kooner; Markku Laakso; Claudia Langenberg; Mark I McCarthy; James S Pankow; Oluf Pedersen; Elio Riboli; Jerome I Rotter; Danish Saleheen; Nilesh J Samani; Heribert Schunkert; Peter Vollenweider; Stephen O'Rahilly; Panos Deloukas; John Danesh; Mark O Goodarzi; Sekar Kathiresan; James B Meigs; Margaret G Ehm; Nicholas J Wareham; Dawn M Waterworth Journal: Sci Transl Med Date: 2016-06-01 Impact factor: 17.956
Authors: Christine Berndt-Zipfel; Georg Michelson; Markus Dworak; Michael Mitry; Andrea Löffler; Andreas Pfützner; Thomas Forst Journal: Cardiovasc Diabetol Date: 2013-04-08 Impact factor: 9.951